Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma.

Bhawna Sirohi1, Ray Powles

  • 1Institute of Cancer Research and Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

Lancet (London, England)
|March 20, 2004
PubMed
Summary
This summary is machine-generated.

Recent advances in multiple myeloma treatment have significantly improved patient outcomes. Novel therapies, including biological treatments, offer new hope for longer survival and remission in this plasma cell malignancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging trends in the global burden of colorectal cancer.

Nature reviews. Clinical oncology·2026
Same author

Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy.

BMC cancer·2026
Same author

Common sense oncology values to action: a patient led framework for randomized clinical trial design.

Journal of the National Cancer Institute·2026
Same author

Barriers to cure in advanced non-seminomatous germ cell tumors: a clinical audit from a resource-limited region in India.

BMC research notes·2026
Same author

Cytokine use in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS): implications for the role of cytokines in a mass casualty radiologic/nuclear (R/N) emergency.

Journal of radiological protection : official journal of the Society for Radiological Protection·2026
Same author

Real-world outcomes of low-dose nivolumab in advanced malignancies.

Journal of cancer research and therapeutics·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Multiple myeloma is a plasma cell malignancy characterized by bone lesions, monoclonal proteins, and bone marrow involvement.
  • Treatment paradigms have evolved significantly over the last decade.

Purpose of the Study:

  • To summarize the current state of multiple myeloma treatment.
  • To highlight advancements in chemotherapy, supportive care, and novel biological therapies.

Main Methods:

  • Review of current treatment protocols for multiple myeloma.
  • Incorporation of supportive care, infusional chemotherapy, high-dose melphalan, and autologous transplantation.
  • Integration of emerging biological treatments targeting myeloma cells and the bone marrow microenvironment.

Related Experiment Videos

Main Results:

  • Younger patients (<70 years) show doubled median survival (5 years) and improved long-term survival rates (20% >10 years).
  • High rates of complete remission (50%) are achievable with modern treatment regimens.
  • Bisphosphonates are crucial for managing bone disease.

Conclusions:

  • Modern treatment strategies have dramatically improved multiple myeloma patient survival and remission rates.
  • Biological therapies targeting disease pathogenesis represent the future of multiple myeloma management.
  • Multidisciplinary care, including bisphosphonates and novel agents, is essential for optimal outcomes.